125 related articles for article (PubMed ID: 38718138)
1. Persistent GDNF Expression 45 Months after Putaminal Infusion of AAV2-GDNF in a Patient with Parkinson's Disease.
Heiss JD; Ray-Chaudhury A; Kleiner DE; Ehrlich DJ; Scott G; Edwards NA; Goldstein DS; Hammoud DA; Hadaczek P; Van Laar VS; Graff SA; Herscovitch P; Lungu C; Hallett M; Lonser RR; Zaghloul KA; Bankiewicz KS
Mov Disord; 2024 May; ():. PubMed ID: 38718138
[TBL] [Abstract][Full Text] [Related]
2. Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys.
Johnston LC; Eberling J; Pivirotto P; Hadaczek P; Federoff HJ; Forsayeth J; Bankiewicz KS
Hum Gene Ther; 2009 May; 20(5):497-510. PubMed ID: 19203243
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson's disease.
Rocco MT; Akhter AS; Ehrlich DJ; Scott GC; Lungu C; Munjal V; Aquino A; Lonser RR; Fiandaca MS; Hallett M; Heiss JD; Bankiewicz KS
Mol Ther; 2022 Dec; 30(12):3632-3638. PubMed ID: 35957524
[TBL] [Abstract][Full Text] [Related]
4. Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease.
Heiss JD; Lungu C; Hammoud DA; Herscovitch P; Ehrlich DJ; Argersinger DP; Sinharay S; Scott G; Wu T; Federoff HJ; Zaghloul KA; Hallett M; Lonser RR; Bankiewicz KS
Mov Disord; 2019 Jul; 34(7):1073-1078. PubMed ID: 31145831
[TBL] [Abstract][Full Text] [Related]
5. Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF.
Kells AP; Eberling J; Su X; Pivirotto P; Bringas J; Hadaczek P; Narrow WC; Bowers WJ; Federoff HJ; Forsayeth J; Bankiewicz KS
J Neurosci; 2010 Jul; 30(28):9567-77. PubMed ID: 20631185
[TBL] [Abstract][Full Text] [Related]
6. Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys.
Su X; Kells AP; Huang EJ; Lee HS; Hadaczek P; Beyer J; Bringas J; Pivirotto P; Penticuff J; Eberling J; Federoff HJ; Forsayeth J; Bankiewicz KS
Hum Gene Ther; 2009 Dec; 20(12):1627-40. PubMed ID: 19671001
[TBL] [Abstract][Full Text] [Related]
7. Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease.
Richardson RM; Kells AP; Rosenbluth KH; Salegio EA; Fiandaca MS; Larson PS; Starr PA; Martin AJ; Lonser RR; Federoff HJ; Forsayeth JR; Bankiewicz KS
Mol Ther; 2011 Jun; 19(6):1048-57. PubMed ID: 21343917
[TBL] [Abstract][Full Text] [Related]
8. Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys.
Eberling JL; Kells AP; Pivirotto P; Beyer J; Bringas J; Federoff HJ; Forsayeth J; Bankiewicz KS
Hum Gene Ther; 2009 May; 20(5):511-8. PubMed ID: 19254173
[TBL] [Abstract][Full Text] [Related]
9. GDNF delivery for Parkinson's disease.
Patel NK; Gill SS
Acta Neurochir Suppl; 2007; 97(Pt 2):135-54. PubMed ID: 17691299
[TBL] [Abstract][Full Text] [Related]
10. Anterograde axonal transport of AAV2-GDNF in rat basal ganglia.
Ciesielska A; Mittermeyer G; Hadaczek P; Kells AP; Forsayeth J; Bankiewicz KS
Mol Ther; 2011 May; 19(5):922-7. PubMed ID: 21102559
[TBL] [Abstract][Full Text] [Related]
11. Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain.
Kells AP; Forsayeth J; Bankiewicz KS
Neurobiol Dis; 2012 Nov; 48(2):228-35. PubMed ID: 22019719
[TBL] [Abstract][Full Text] [Related]
12. Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation.
Patel NK; Pavese N; Javed S; Hotton GR; Brooks DJ; Gill SS
Neurology; 2013 Sep; 81(13):1176-8. PubMed ID: 23946313
[TBL] [Abstract][Full Text] [Related]
13. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys.
Herzog CD; Dass B; Holden JE; Stansell J; Gasmi M; Tuszynski MH; Bartus RT; Kordower JH
Mov Disord; 2007 Jun; 22(8):1124-32. PubMed ID: 17443702
[TBL] [Abstract][Full Text] [Related]
14. Glial Cell Line-Derived Neurotrophic Factor Gene Delivery in Parkinson's Disease: A Delicate Balance between Neuroprotection, Trophic Effects, and Unwanted Compensatory Mechanisms.
Tenenbaum L; Humbert-Claude M
Front Neuroanat; 2017; 11():29. PubMed ID: 28442998
[TBL] [Abstract][Full Text] [Related]
15. Adeno-associated virus type 2 vector-mediated glial cell line-derived neurotrophic factor gene transfer induces neuroprotection and neuroregeneration in a ubiquitin-proteasome system impairment animal model of Parkinson's disease.
Du Y; Zhang X; Tao Q; Chen S; Le W
Neurodegener Dis; 2013; 11(3):113-28. PubMed ID: 22626907
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease.
Bäck S; Peränen J; Galli E; Pulkkila P; Lonka-Nevalaita L; Tamminen T; Voutilainen MH; Raasmaja A; Saarma M; Männistö PT; Tuominen RK
Brain Behav; 2013 Mar; 3(2):75-88. PubMed ID: 23532969
[TBL] [Abstract][Full Text] [Related]
17. Safety Assessment of AAV2-hGDNF Administered Via Intracerebral Injection in Rats for Treatment of Parkinson's Disease.
Terse PS; Kells AP; Noker P; Wright JF; Bankiewicz KS
Int J Toxicol; 2021; 40(1):4-14. PubMed ID: 33131343
[TBL] [Abstract][Full Text] [Related]
18. Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors.
Su X; Kells AP; Salegio EA; Salegio EA; Richardson RM; Hadaczek P; Beyer J; Bringas J; Pivirotto P; Forsayeth J; Bankiewicz KS
Mol Ther; 2010 Aug; 18(8):1490-5. PubMed ID: 20551915
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease.
Whone A; Luz M; Boca M; Woolley M; Mooney L; Dharia S; Broadfoot J; Cronin D; Schroers C; Barua NU; Longpre L; Barclay CL; Boiko C; Johnson GA; Fibiger HC; Harrison R; Lewis O; Pritchard G; Howell M; Irving C; Johnson D; Kinch S; Marshall C; Lawrence AD; Blinder S; Sossi V; Stoessl AJ; Skinner P; Mohr E; Gill SS
Brain; 2019 Mar; 142(3):512-525. PubMed ID: 30808022
[TBL] [Abstract][Full Text] [Related]
20. Slowing of EEG waves correlates with striatal [
Lorek K; Mączewska J; Królicki L; Siemiatycka M; Chalimoniuk M; Kisiel-Sajewicz K; Marusiak J
Eur J Neurosci; 2023 Nov; 58(9):4070-4083. PubMed ID: 37787445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
